Pharmacodynamic Equivalence of Ovine Enoxaparin to Lovenox®
Status:
Completed
Trial end date:
2020-05-03
Target enrollment:
Participant gender:
Summary
This study is designed as a randomized, open-label, 2-way cross-over, single dose study with
at least 7 days wash-out period. The objective of this study is to demonstrate the
pharmacodynamic / pharmacokinetic equivalence of ovine enoxaparin to the reference product,
the originator porcine enoxaparin, Lovenox® from Sanofi, and to assess its safety and
tolerability in healthy volunteers.